Overview

Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver Cirrhosis

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
This trial was intended to investigate the pharmacokinetics, safety and tolerability of BI 201335 NA soft-gel capsules in patients with compensated liver cirrhosis, i.e. grade A according to Child-Pugh classification (< 7 points).
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim